BeiGene (BGNE) experienced a significant surge in its stock price, soaring 5.37% in the 24-hour period leading up to Friday's trading session. This remarkable increase followed the announcement that four of the company's drugs were included in China's national medical insurance catalog.
According to a filing with the Shanghai Stock Exchange on Friday, China's medical products administrator has approved the inclusion of BeiGene's Tislelizumab and Zebutinib for tumors, Baituowei for prostate and breast cancer, and Carfilzomib for myeloma in the national medical insurance catalog. This pivotal decision means that these drugs will now be covered under the country's healthcare system, potentially increasing their accessibility and affordability for patients.
The news was well-received by investors, as BeiGene's shares rose 5% in Hong Kong and 3% in Shanghai during Friday's trading session. Analysts view this development as a significant milestone for the biopharmaceutical company, as it solidifies its position in the Chinese market and opens up new avenues for revenue growth through increased sales of these four drugs.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。